Biomarkers for predicting prognosis after immunotherapy of cancer

摘要

The present invention relates to a biomarker for selecting a patient for which the occurrence of immune-related adverse events (irAEs) is predicted after treatment with an immunotherapy (PD-1/PD-L1). It is expected that cancer patients, especially thymoma and non-small cell lung cancer patients, can predict the occurrence of irAEs prior to the use of immune anti-cancer drugs, thereby making it possible to determine whether or not to use immuno-anti-cancer drugs for non-small cell lung cancer patients, thereby prolonging life expectancy.